Swedish Orphan Biovitrum AB (publ) (SWOBY) Analyst/Investor Day Transcript

SA Transcripts158.48K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Swedish Orphan Biovitrum AB (publ) (SWOBY) Analyst/Investor Day February 18, 2026 7:00 AM EST Company Participants Gerard Tobin - Head of Investor RelationsGuido Oelkers - CEO & PresidentLydia Abad-Franch - Senior VP, Head of R&D & Medical Affairs and Chief Medical OfficerRobert KeenanDuane Barnes - Head of North AmericaSofiane Fahmy - Head of EuropeNorbert Oppitz - Head of InternationalHenrik Stenqvist - Chief Financial Officer Conference Call Participants Klaus ParhoferEvangelos GiamarellosViktor Sundberg - Nordea Markets, Research DivisionChristopher Uhde - SEB, Research DivisionGonzalo Artiach Castanon - Danske Bank A/S, Research DivisionErik HultgardMattias Häggblom - Handelsbanken Capital Markets AB, Research DivisionKirsty Ross-Stewart - BNP Paribas, Research DivisionHarry Gillis - Joh. Berenberg, Gossler & Co. KG, Research DivisionBenjamin Jackson - Jefferies LLC, Research DivisionXue Chen - Barclays Bank PLC, Research Division Presentation Gerard TobinHead of Investor Relations Hello, everybody, and welcome to everyone who's here today in Stockholm and also to everyone who's joining us online for Sobi's Capital Market Day 2026. I hope you'll find this session in the next few hours valuable, and I hope you feel some of the real excitement that we feel about Sobi right now in terms of the progression of the company and also some of the really exciting medicines that we have in our development pipeline, which we want to bring to many patients around the world. So to get us started, I just want to please take note of the standard forward-looking statements. I just want to take a minute to briefly go through what you'll expect for the Capital Markets Day in the next few hours. We will have an opening session by Guido, which will take us through the strategy and our new 2030 outlook. Then that will be followed by Lydia, who will go through some of the exciting developments we have in our clinical development